Treatment and progression of patients in Sweden with metastatic castration-sensitive prostate cancer - PubMed
2 hours ago
- #mCSPC
- #prostate cancer
- #Sweden
- The study examines treatment and progression outcomes in Swedish patients with metastatic castration-sensitive prostate cancer (mCSPC) from 2017-2023.
- Median time to progression or death improved from 19.9 months (2017-2020) to 30.0 months (2021-2023), with a rise in use of initial doublet/triplet therapy from 42.5% to 68.8%.
- Overall survival remained stable at 49.8 months, showing no significant difference between the two time periods analyzed.